Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci134 in pediatric growth hormone deficiency (Ib/II dose-finding vs Norditropin)
CTR20260174Phase 2Active
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- May 2026
- Countries
- 1
01
Overview
A Phase 2 trial of GenSci134 in growth hormone deficiency (GHD), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started May 2026; status: active.
02
Drugs
GenSci134
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on CTR20260174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260174.